United Therapeutics Corporation announced record financial results for the second quarter ended June 30, 2025, with total revenues growing 12% year-over-year to $798.6 million. This marks the company's 12th consecutive quarter of double-digit year-over-year total revenue growth.
Net income for the quarter was $309.5 million, an 11% increase from the prior year, and diluted earnings per share reached $6.41, up 10%. Tyvaso DPI continued to be a primary growth driver, with revenues of $315.2 million, up 22% year-over-year, while Orenitram and Unituxin also showed double-digit revenue growth.
The Board of Directors authorized a new $1 billion share repurchase program, set to expire in March 2026, reflecting confidence in the company's intrinsic value and upcoming catalysts. Additionally, the Phase 3 TETON 2 study for nebulized Tyvaso in idiopathic pulmonary fibrosis is complete with data expected in September 2025, and enrollment for the ADVANCE OUTCOMES study of ralinepag is complete with data expected in the first half of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.